scholarly journals CD20+ B Cell Depletion in Systemic Autoimmune Diseases: Common Mechanism of Inhibition or Disease-Specific Effect on Humoral Immunity?

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Panagiotis Pateinakis ◽  
Athina Pyrpasopoulou
Keyword(s):  
Autoimmune Diseases ◽  
B Cell ◽  
Specific Effect ◽  
Cell Depletion ◽  
Common Mechanism ◽  
B Cell Depletion ◽  
Systemic Autoimmune Diseases ◽  
Mechanism Of Inhibition ◽  
End Effectors ◽  
Disease Specific

Autoimmunity remains a complex physiologic deviation, enabled and perpetuated by a variety of interplayers and pathways. Simplistic approaches, targeting either isolated end-effectors of more centrally placed interactors of these mechanisms, are continuously tried in an effort to comprehend and halt cascades with potential disabling and deleterious effects in the affected individuals. This review focuses on theoretical and clinically proved effects of rituximab-induced CD20+ B cell depletion on different systemic autoimmune diseases and extrapolates on pathogenetic mechanisms that may account for different interindividual or interdisease responses.

B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases

2013 ◽  
Vol 43 ◽  
pp. 55-59 ◽  
Author(s):  
Shirish R. Sangle ◽  
Pamela M.K. Lutalo ◽  
Rachel J. Davies ◽  
Munther A. Khamashta ◽  
David P. D'Cruz
Keyword(s):  
Autoimmune Diseases ◽  
B Cell ◽  
Pregnancy Outcome ◽  
Cell Depletion ◽  
B Cell Depletion ◽  
Systemic Autoimmune Diseases

B-cell depletion in autoimmune diseases

2009 ◽  
Vol 8 (7) ◽  
pp. 585-590 ◽  
Author(s):  
Renato Guzman Moreno
Keyword(s):  
Autoimmune Diseases ◽  
B Cell ◽  
Cell Depletion ◽  
B Cell Depletion

B-Cell Depletion and Repopulation in Autoimmune Diseases

2007 ◽  
Vol 34 (1) ◽  
pp. 50-55 ◽  
Author(s):  
Jacques-Olivier Pers ◽  
Capucine Daridon ◽  
Boutahar Bendaoud ◽  
Valérie Devauchelle ◽  
Christian Berthou ◽  
...  
Keyword(s):  
Autoimmune Diseases ◽  
B Cell ◽  
Cell Depletion ◽  
B Cell Depletion

Anti-CD20–mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives

2020 ◽  
Vol 97 (5) ◽  
pp. 885-893 ◽  
Author(s):  
Etienne Crickx ◽  
Jean-Claude Weill ◽  
Claude-Agnès Reynaud ◽  
Matthieu Mahévas
Keyword(s):  
Autoimmune Diseases ◽  
B Cell ◽  
Cell Depletion ◽  
B Cell Depletion ◽  
Future Perspectives ◽  
Anti Cd20

scholarly journals P74 Rituximab effect on B cell depletion in paediatric patients with autoimmune diseases: a retrospective dose-response analysis of an observational study

2019 ◽  
Vol 104 (6) ◽  
pp. e47.3-e48
Author(s):  
S Pan ◽  
H Yu ◽  
A Surti ◽  
I Cheng ◽  
SD Marks ◽  
...  
Keyword(s):  
Autoimmune Diseases ◽  
B Cell ◽  
Dose Response ◽  
Death Rate ◽  
Cell Depletion ◽  
List Type ◽  
B Cell Depletion ◽  
Electronic Health Record Data ◽  
Street Hospital ◽  
Rebound Increase

BackgroundRituximab is a chimeric IgG1 monoclonal antibody that depletes B cells for the treatment of several conditions including autoimmune diseases. It is not licensed for use in children but administered off-label. This study aimed to quantify the effect of rituximab on B cell depletion in children with autoimmune diseases and to optimise the dosing regimen.MethodsElectronic health record data were collected from a retrospective and anonymised study at Great Ormond Street Hospital in London. Dosing protocols of rituximab were two 750 mg/m2 intravenous infusions or four weekly 375 mg/m2 infusions. Serum concentrations of rituximab were not measured. CD19+ lymphocyte counts were taken before and after rituximab treatment. A turnover mechanism described the life cycle of CD19+ lymphocytes with rituximab increasing the death rate of CD19+ lymphocytes; a negative feedback was added on the production rate to examine the rebound effect. Rituximab was assumed to decay by first-order kinetics.Results258 measurements of CD19+ lymphocyte counts were collected from 39 children with 8 autoimmune diseases. The dose-response model well described the time course of CD19+ lymphocytes following rituximab administration. The elimination half-lives of rituximab and CD19+ lymphocytes were estimated to be 19 and 35 days, respectively, consistent with findings from other studies [1–5]. The rebound increase in CD19+ lymphocytes was found negligible. Methotrexate and cyclophosphamide increased the maximum death rate by 66% and 38% respectively. Age and gender were not significant covariates.Simulations from the model suggested that a single infusion of rituximab of 375 mg/m2 can provide similar six-month suppression of CD19+ lymphocytes to the higher doses currently used. Methotrexate or cyclophosphamide added minimal suppression effect on CD19+ lymphocytes when taken concurrently with rituximab.ConclusionsOur results could be used in future to assess the effect of rituximab biosimilars and to inform biosimilar dosing in paediatric populations.ReferencesNg, et al. J Clin Pharmacol. 2005; 45:792–801Li, et al. Blood. 2007; 110:2371Li, et al. J Clin Pharmacol. 2012; 52:1918–26Fulcher and Basten. Immunol Cell Biol. 1997; 75:446–55Macallan, et al. Blood. 2005; 105:3633–40Disclosure(s)Nothing to disclose

Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells

2008 ◽  
Vol 127 (3) ◽  
pp. 280-285 ◽  
Author(s):  
Stamatis-Nick C. Liossis ◽  
Petros P. Sfikakis
Keyword(s):  
T Cells ◽  
Autoimmune Diseases ◽  
B Cell ◽  
Cell Depletion ◽  
B Cell Depletion
Sign in / Sign up

Export Citation Format

Share Document